Breaking News Instant updates and real-time market news.

GHDX

Genomic Health

$31.29

0.15 (0.48%)

08:21
03/30/18
03/30
08:21
03/30/18
08:21

Epic, Genomic announce favorable draft local coverage determination

Epic Sciences and Genomic Health (GHDX) announced that Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, has issued a draft local coverage determination for the Oncotype DX AR-V7 Nucleus Detect test. The draft LCD recommends Medicare coverage for use of the test throughout the United States to help determine which patients with metastatic castration-resistant prostate cancer may benefit from androgen receptor signaling inhibitor (ARSi) therapy and which may benefit from chemotherapy, the companies said in a statement. The Oncotype DX AR-V7 Nucleus Detect test is a circulating tumor cell-based, liquid biopsy test that is commercially available in the United States through Epic's partnership with Genomic Health. "Prior to the Oncotype DX AR-V7 Nucleus Detect test, there was no clear consensus on therapeutic sequencing after initial exposure to an ARSi therapy, and the most common clinical decision in mCRPC was whether to start a second ARSi or taxane chemotherapy," Epic and Genomic write. Murali Prahalad, CEO of Epic Sciences, said, "The rapid issuance of the draft LCD recommending Medicare coverage highlights the clinical utility and value of this new test in prolonging survival for men with metastatic castration-resistant prostate cancer."

GHDX Genomic Health
$31.29

0.15 (0.48%)

09/29/17
ADAM
09/29/17
NO CHANGE
Target $40
ADAM
Buy
Genomic Health price target raised to $40 from $35 at Canaccord
Following meetings with management, Canaccord analyst Mark Massaro raised his price target on Genomic Health to $40 from $35, citing his expectations for it to achieve double digit growth and accelerate levels of profitability in 2018 and 2019. The analyst believes the shares could hit $40 in early 2018. Massaro reiterated his Buy rating on Genomic Health shares.
12/13/17
JPMS
12/13/17
DOWNGRADE
Target $25
JPMS
Underweight
Genomic Health downgraded to Underweight from Neutral at JPMorgan
JPMorgan analyst Tycho Peterson downgraded Genomic Health to Underweight and cut his price target for the shares to $25 from $28. The analyst believes the company will be challenged to outgrow a maturing market for its core U.S. invasive breast business. He sees better risk/reward opportunities in other names.
12/20/17
WBLR
12/20/17
DOWNGRADE
WBLR
Market Perform
Genomic Health downgraded to Market Perform from Outperform at William Blair
William Blair analyst Amanda Murphy downgraded Genomic Health to Market Perform citing valuation with the shares rallying recently on reports of a potential sale.
01/10/18
COWN
01/10/18
NO CHANGE
COWN
Market Perform
NICE guidance on Genomic Health test 'somewhat surprising,' says Cowen
Cowen analyst Doug Schenkel noted that the U.K.'s National Institute for Health and Care Excellence, or NICE, reversed a previous decision with new draft guidance that does not recommend Genomic Health's Oncotype test in guiding chemotherapy decisions for breast cancer patients. He finds this "somewhat surprising" given the test's inclusion in other international guidelines and think this could lead to some slight tempering of expectations if finalized. Schenkel has a Market Perform rating on Genomic Health shares.

TODAY'S FREE FLY STORIES

ZAYO

Zayo Group

$24.05

1.54 (6.84%)

07:01
11/14/18
11/14
07:01
11/14/18
07:01
Recommendations
Zayo Group analyst commentary  »

Zayo Group price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

HD

Home Depot

06:59
11/14/18
11/14
06:59
11/14/18
06:59
Recommendations
Home Depot analyst commentary  »

Home Depot price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$78.90

0.04 (0.05%)

06:59
11/14/18
11/14
06:59
11/14/18
06:59
Recommendations
NetApp analyst commentary  »

NetApp positioned as…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

AAP

Advance Auto Parts

$184.66

17.72 (10.61%)

06:58
11/14/18
11/14
06:58
11/14/18
06:58
Recommendations
Advance Auto Parts analyst commentary  »

Advance Auto Parts price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$58.67

-0.05 (-0.09%)

06:58
11/14/18
11/14
06:58
11/14/18
06:58
Periodicals
Verizon aims to widen 5G home broadband offering, Reuters reports »

Verizon is looking to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 26

    Nov

W

Wayfair

$92.66

0.97 (1.06%)

06:56
11/14/18
11/14
06:56
11/14/18
06:56
Syndicate
Breaking Syndicate news story on Wayfair »

Wayfair files to sell…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

KALA

Kala Pharmaceuticals

$6.56

0.09 (1.39%)

06:55
11/14/18
11/14
06:55
11/14/18
06:55
Recommendations
Kala Pharmaceuticals analyst commentary  »

Kala Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

OI

Owens-Illinois

$16.76

0.55 (3.39%)

06:52
11/14/18
11/14
06:52
11/14/18
06:52
Hot Stocks
Owens-Illinois initiates dividend of 5c, raises share repurchase to $600M »

The company announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

PENN

Penn National

$19.76

-0.3 (-1.50%)

06:52
11/14/18
11/14
06:52
11/14/18
06:52
Recommendations
Penn National analyst commentary  »

Penn National added to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MTOR

Meritor

$16.82

-0.08 (-0.47%)

06:51
11/14/18
11/14
06:51
11/14/18
06:51
Earnings
Meritor sees FY19 adj. EPS about $3.10, consensus $3.32 »

Sees FY19 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 06

    Dec

  • 13

    Dec

LLY

Eli Lilly

$111.85

-0.77 (-0.68%)

06:51
11/14/18
11/14
06:51
11/14/18
06:51
Hot Stocks
Eli Lilly submits NDA for lasmiditan, gets breakthrough designation for Emgality »

Eli Lilly has announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

06:50
11/14/18
11/14
06:50
11/14/18
06:50
General news
European stock markets pared some of their losses »

European stock markets…

GOOS

Canada Goose

$58.60

1.51 (2.64%)

06:49
11/14/18
11/14
06:49
11/14/18
06:49
Earnings
Canada Goose raises FY19 adj. EPS growth view to at least 25% from at least 40% »

Consensus for FY19 EPS is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

SGMO

Sangamo

$10.80

0.8 (8.00%)

, BMRN

BioMarin

$93.51

0.43 (0.46%)

06:49
11/14/18
11/14
06:49
11/14/18
06:49
Downgrade
Sangamo, BioMarin, Spark Therapeutics rating change  »

JPMorgan downgrades…

SGMO

Sangamo

$10.80

0.8 (8.00%)

BMRN

BioMarin

$93.51

0.43 (0.46%)

ONCE

Spark Therapeutics

$42.74

1.12 (2.69%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

MTOR

Meritor

$16.82

-0.08 (-0.47%)

06:49
11/14/18
11/14
06:49
11/14/18
06:49
Earnings
Meritor reports Q4 adj. EPS 82c, consensus 71c »

Reports Q4 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 06

    Dec

  • 13

    Dec

MRK

Merck

$74.62

-0.06 (-0.08%)

06:48
11/14/18
11/14
06:48
11/14/18
06:48
Hot Stocks
Merck: Phase 3 KEYNOTE-181 trial met a primary endpoint of overall survival »

Merck announced that the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 11

    Jan

  • 16

    Feb

WFC

Wells Fargo

$52.74

0.38 (0.73%)

06:47
11/14/18
11/14
06:47
11/14/18
06:47
Periodicals
Departure of top Wells Fargo exec Hardison shows rift with regulator, WSJ says »

Hope Hardison, Wells…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 15

    Nov

  • 12

    Apr

  • 13

    Jul

  • 12

    Oct

TRU

TransUnion

$64.43

-0.41 (-0.63%)

06:47
11/14/18
11/14
06:47
11/14/18
06:47
Hot Stocks
TransUnion CEO James Peck to retire, Chris Cartwright to succeed »

TransUnion announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

GOOS

Canada Goose

$58.60

1.51 (2.64%)

06:46
11/14/18
11/14
06:46
11/14/18
06:46
Earnings
Canada Goose reports Q2 adjusted EPS 46c, consensus (7c) »

Reports Q2 revenue…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

K

Kellogg

$63.48

-0.81 (-1.26%)

, GIS

General Mills

$45.50

-0.2 (-0.44%)

06:46
11/14/18
11/14
06:46
11/14/18
06:46
Downgrade
Kellogg, General Mills, Kraft Heinz rating change  »

JPMorgan downgrades…

K

Kellogg

$63.48

-0.81 (-1.26%)

GIS

General Mills

$45.50

-0.2 (-0.44%)

KHC

Kraft Heinz

$53.38

-0.29 (-0.54%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Mar

06:45
11/14/18
11/14
06:45
11/14/18
06:45
General news
Breaking General news story  »

Week of 11/9 MBA Mortgage…

JNCE

Jounce Therapeutics

$4.40

-0.06 (-1.35%)

06:40
11/14/18
11/14
06:40
11/14/18
06:40
Downgrade
Jounce Therapeutics rating change  »

JPMorgan downgrades…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AMZN

Amazon.com

$1,631.68

-5.02 (-0.31%)

06:38
11/14/18
11/14
06:38
11/14/18
06:38
Periodicals
Amazon says over 10,000 workers are developing Alexa, Echo, WSJ reports »

Amazon has over 10,000…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 28

    Nov

  • 04

    Dec

NOVN

Novan

$2.50

-0.04 (-1.57%)

06:38
11/14/18
11/14
06:38
11/14/18
06:38
Hot Stocks
Novan Phase 2 molluscum contagiosum trial achieves statistical significance »

Novan announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 14

    Nov

  • 27

    Nov

LLESY

Lendlease Group

$0.00

(0.00%)

06:37
11/14/18
11/14
06:37
11/14/18
06:37
Upgrade
Lendlease Group rating change  »

Lendlease Group upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.